Patel Sushil 4

What Happened

• Sushil Patel, CEO of Replimune Group, received equity awards on April 1, 2026: 251,240 restricted stock units (RSUs) and 376,860 derivative awards (stock-option–style grant). Both awards were reported at $0.00 per share (i.e., granted, not purchased), for a combined total of 628,100 shares subject to future vesting/settlement. This is an award/grant transaction (code A), not a sale.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-07 (late filing; see below).
• Grant amounts and reported price:
  • 251,240 RSUs @ $0.00 (F1)
  • 376,860 derivative award @ $0.00 (F2)
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Vesting notes:
  • F1 (RSUs): 25% vest May 15, 2027; remaining RSUs vest in three approximately equal annual installments through May 15, 2030, subject to continued service.
  • F2 (derivative/option): 25% of shares underlying the option vest April 1, 2027; remaining shares vest in ~36 equal monthly installments thereafter.
• Filing timeliness: The Form 4 was filed late; the filing states the delay was due to an inadvertent administrative error.

Context

• These awards are standard compensation grants and represent future rights to shares contingent on vesting/settlement; they are not open‑market purchases or sales. The derivative award follows a multi-year vesting schedule (partial cliff then monthly vesting). A late Form 4 does not change the nature of the grant but reduces disclosure timeliness for investors.